127 related articles for article (PubMed ID: 24138720)
1. Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
Galvani E; Toffalorio F; Peters GJ; De Pas T; Giovannetti E
Curr Pharm Des; 2014; 20(24):3863-74. PubMed ID: 24138720
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
Giovannetti E; Toffalorio F; De Pas T; Peters GJ
Pharmacogenomics; 2012 Jul; 13(9):1073-86. PubMed ID: 22838953
[TBL] [Abstract][Full Text] [Related]
3. On the pharmacogenetics of non-small cell lung cancer treatment.
Santarpia M; Rolfo C; Peters GJ; Leon LG; Giovannetti E
Expert Opin Drug Metab Toxicol; 2016; 12(3):307-17. PubMed ID: 26761638
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.
Yin JY; Huang Q; Zhao YC; Zhou HH; Liu ZQ
PLoS One; 2012; 7(6):e38150. PubMed ID: 22761669
[TBL] [Abstract][Full Text] [Related]
6. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Sito H; Tan SC
Mol Biol Rep; 2024 Jan; 51(1):102. PubMed ID: 38217759
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
11. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer.
Danesi R; Pasqualetti G; Giovannetti E; Del Tacca M
J Thorac Oncol; 2007 May; 2(5 Suppl):S27-30. PubMed ID: 17457227
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.
Yin JY; Li X; Zhou HH; Liu ZQ
Pharmacogenomics; 2016 Aug; 17(12):1365-78. PubMed ID: 27462924
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer.
Rose MC; Kostyanovskaya E; Huang RS
Genomics Proteomics Bioinformatics; 2014 Oct; 12(5):198-209. PubMed ID: 25449594
[TBL] [Abstract][Full Text] [Related]
16. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
17. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
18. Approaching the increasing complexity of non-small cell lung cancer taxonomy.
Maugeri-Sacca M; Bartucci M; Pagliuca A; Patrizii M; Signore M; De Maria R
Curr Pharm Des; 2014; 20(24):3973-81. PubMed ID: 24138717
[TBL] [Abstract][Full Text] [Related]
19. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
Schnabel PA; Smit E; Carpeño Jde C; Leśniewski-Kmak K; Aerts J; Kraaij K; Visseren-Grul C; Dyachkova Y; Taipale K; Girvan A; Moro-Sibilot D
Lung Cancer; 2012 Dec; 78(3):263-9. PubMed ID: 23040326
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
